Education
About Us
Working with TipRanks
Follow Us
Mangalam Drugs & Organics Ltd. (IN:MANGALAM)
:MANGALAM
MANGALAM Stock Chart & Stats
₹30.40
-₹1.02(-0.89%)
At close: 4:00 PM EST
₹30.40
-₹1.02(-0.89%)
Day’s Range― - ―
52-Week Range₹22.70 - ₹107.90
Previous CloseN/A
Volume15.57K
Average Volume (3M)5.11K
Market Cap
₹475.80M
Enterprise Value₹1.38B
Total Cash (Recent Filing)₹25.89M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.95
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.21
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)0.84
Price to Sales (P/S)0.39
P/FCF Ratio5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Specialty Chemicals & API SupplierMangalam’s focus on specialty chemicals and pharmaceutical intermediates creates durable B2B demand. Regulatory and quality barriers in pharma supply chains produce sticky customer relationships and higher switching costs, supporting steady order pipelines and long-term revenue resilience.
Manageable Leverage / Balanced Balance SheetA balanced capital structure and consistent stockholders' equity give the company flexibility to fund operations and absorb shocks. Manageable leverage supports credit access for working capital and selective capex, reducing refinancing risk during industry cycles over the next several months.
Improving Operating Cash FlowStronger operating cash flow relative to net income indicates improved cash conversion from core operations, enabling internal funding for working capital and maintenance capex. Sustained OCF improvement bolsters financial stability and reduces reliance on external financing over time.
Bears Say
Declining Revenue And Net IncomeFalling revenue and net income signal weaker demand or pricing pressure in core products. This erodes operating leverage and constrains reinvestment capacity, making it harder to stabilize margins or fund growth initiatives without sustained recovery in sales volumes or price realization.
Contracting EBIT/EBITDA MarginsMargin compression reduces the buffer against cost shocks and limits free cash generation. If persistent, contracted operating margins will hamper ability to invest in higher-margin specialty lines, and increase sensitivity to raw material and input-cost volatility across future quarters.
Rising Total Debt RiskAn upward trend in total debt raises leverage vulnerability if earnings remain weak. Combined with shrinking revenue and uneven FCF, higher debt increases interest and refinancing exposure, narrowing strategic flexibility and elevating downside risk in a prolonged cyclical or demand slowdown.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹107.90 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹475.80M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
Mangalam Drugs & Organics Ltd.’s upcoming earnings report date is May 27, 2026 which is in 90 days.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on Jan 15, 2026. The company reported -₹6.214 earnings per share for the quarter, missing the consensus estimate of N/A by -₹6.214.
Is Mangalam Drugs & Organics Ltd. overvalued?
According to Wall Street analysts Mangalam Drugs & Organics Ltd.’s price is currently Overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹6.214 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.
Technical Analysis
Bhageria Industries Ltd.
―
Ganesh Benzoplast Limited
―
HP Adhesives Ltd.
―
Khaitan Chemicals & Fertilizers Ltd.
―
Mangalam Organics Ltd
―